Moritz Bewarder

11PUBLICATIONS
63CO-AUTHORS
Molecular targetsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 21, 2026
Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomas.

|Apr 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma.

Jan H Frenking, Christine Riedhammer, Raphael Teipel

|Dec 17, 2024
Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.

Moritz Bewarder, Konstantinos Christofyllakis, Milena Petersen

|Sep 28, 2024
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.

Sylvia Zöphel, Nadja Küchler, Johanna Jansky

|Aug 19, 2024
Successful treatment of refractory donor-specific-human leukocyte antigen-antibody-induced primary graft-failure with daratumumab: A case report.

Vadim Lesan, Ketevani Melivadze, Johannes Hein

|Apr 29, 2024
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.

Philipp M Roessner, Isabelle Seufert, Vicente Chapaprieta

Pageof 2

Frequent Collaborators

4 joint publications

Lorenz Thurner

2 joint publications

Igor Kos

2 joint publications

Eva C Schwarz

2 joint publications

Frank Neumann